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Abstract
Background Following reports of discoloration, including
retinal pigmentation, in addition to known significant risks
of urinary retention, central nervous system effects, and
QTc prolongation, the retigabine indication was restricted
to adjunctive treatment of partial onset seizures where
other appropriate drug combinations have proved inade-
quate or have not been tolerated.
Objective To ascertain the effectiveness of educational
initiatives as reflected in physicians’ understanding of
retigabine-associated risks, management, and patient
selection.
Methodology An online, cross-sectional survey, desig-
nated a post-authorization safety study (24/9/2014–30/1/
2015), recruited retigabine prescribers (RP) and retigabine
non-prescribers (RNP) in seven countries, who had been
sent a retigabine Dear Health Care Professional letter (June
2013). Questions tested understanding of the significant
risks associated with retigabine.
Results 414/467 participants completed all questions (RP,
n = 141; RNP, n = 273) and were included in the analy-
sis. 74.2 % of these participants (RP, 77.3 %; RNP,
72.5 %) correctly identified the label indication. 81.9 % of
participants (RP, 86.5 %; RNP, 79.5 %) recognized that
specific retigabine-associated risks included pigment
changes of ocular tissues, including the retina. 81.6 % of
participants (RP, 87.2 %; RNP, 78.8 %) recognized that a
comprehensive ophthalmologic examination is required.
99.8 % of participants (RP, 100.0 %; RNP, 99.6 %)
acknowledged the requirement for action in case of retinal
pigmentation or vision changes. RP and RNP results were
similar to the overall participants’ analysis, with a trend
toward stronger understanding among RP.
Conclusion Most participants recognized the appropriate
population for retigabine treatment and the requirement to
monitor for adverse events including retinal pigmentation
and vision changes. Understanding was satisfactory among
RNP but stronger among RP.
Key Points
A seven-country survey, following a Dear Health
Care Professional (DHCP) letter, assessed
physicians’ knowledge of the significant risks
associated with retigabine therapy and revisions to
the product information.
Most physicians participating in the survey were
aware of the requirement to monitor for treatment-
emergent adverse events including retinal
pigmentation and vision changes, and could identify
the appropriate population for retigabine treatment.
Understanding was stronger among retigabine
prescribers than non-prescribers, for physicians who
specialized in epilepsy, and for physicians treating
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1 Introduction
Retigabine (TrobaltTM; GlaxoSmithKline [GSK]) was
approved in Europe in March 2011 as adjunctive therapy
for the management of drug-resistant partial-onset seizures
with or without secondary generalization in adults 18 years
and older with epilepsy [1]. The results of randomized
studies comparing retigabine and placebo for efficacy and
safety indicated that although effective, retigabine treat-
ment entailed increased risks of urinary retention, central
nervous system effects (including confusion, hallucina-
tions, and psychotic disorders), and prolongation of the
QTc interval [2–5]. Subsequently, adverse event reports,
and coincidental findings at study visits, of pigmentation/
discoloration were received from long-term, open-label
extension studies and a compassionate use program.
Reports were generally of a blue-grey discoloration of the
nails and/or lips; pigmentation of the skin and retina was
also reported [6]. An increase in such reports over time
prompted a decision by GSK Global Clinical Safety and
Pharmacovigilance in 2013 to restrict the retigabine indi-
cation to adjunctive treatment of drug-resistant partial
onset seizures with or without secondary generalization in
patients aged 18 years and older, where other appropriate
drug combinations have proved inadequate or have not
been tolerated [7]. In addition, warnings of pigment
changes (discoloration) of ocular tissues including the
retina, as well as of the lips, skin, and nails were added to
the Summary of Product Characteristics (SmPC; sec-
tions 4.4 and 4.8) [8], with recommendations for ophthal-
mologic examinations before and during treatment. At the
same time, in the USA, where the drug was marketed as
ezogabine (Potiga), the Food and Drug Administration
(FDA) approved changes to the label describing risks of
abnormalities in the retina, potential vision loss, and skin
discoloration [9, 10]. Attention was drawn to these risks in
a Drug Safety Communication in April 2013 [11].
After educational outreach to neurologists in the first
seven European countries to launch retigabine (Denmark,
Germany, Norway, Slovakia, Spain, Switzerland, and the
UK), focusing on the risks described in the approved
European Union Physician’s Guide for retigabine, results
of a follow-up online survey (November 2012–October
2013) indicated that physicians generally had adequate
knowledge of the indication for retigabine, but had poorer
recall of specific dose-related information and risk man-
agement [12].
Subsequent to the 2012–2013 survey [12], GSK made
further changes to the product labeling for retigabine, and,
in June 2013, sent a Dear Health Care Professional (DHCP)
letter to inform physicians in Europe and Hong Kong of the
revisions to the indication and wording in the SmPC, and
recommending that ophthalmologic examinations be per-
formed at baseline and at least every 6 months thereafter
during treatment with retigabine. The letter also reminded
physicians of the need to assess benefits versus risks when
initiating or continuing retigabine therapy. Following this
initiative, which was specified in the Risk Management
Plan (RMP), the present post-authorization safety study
(PASS) survey was directed to physicians across seven
countries to ascertain the effectiveness of the DHCP letter
and to evaluate physicians’ awareness and knowledge of
the specific risks associated with retigabine (including
retinal pigmentation, skin discoloration, urinary retention,
prolongation of the QTc interval, and psychiatric disor-
ders), management of such risks, new safety-monitoring




The PASS was designed as an online cross-sectional survey
(24 September 2014–30 January 2015) of a sample of
physicians, divided equally between retigabine prescribers
(RP) and retigabine non-prescribers (RNP), who met the
following criteria: (1) they had prescribed an antiepileptic
drug (AED) at least once in the previous 6 months; (2) they
had been sent a retigabine DHCP letter in June 2013; and
(3) they practiced medicine in one of four countries within
the European Union (EU) where retigabine had been used
comparatively often (Belgium, Spain, Slovakia, and the
UK) or three countries outside the EU where retigabine is
available (Switzerland, Norway, and Hong Kong, China).
Physicians were ineligible to participate if they were
employees of GSK or United BioSource Corporation, or
were government officials. Ethics approval was obtained as
required by individual countries, as was regulatory
approval or notification where applicable. Physicians to
whom the DHCP letter had been sent were invited to
participate in the survey by e-mail in Spain and by postal
mail in the other countries, where e-mail addresses were
not available.
The online survey questionnaire consisted of 16 ques-
tions, of which nos. 1–9 were the screening phase and nos.
10–15 were the assessment phase; no. 16 was a purely
administrative question by the independent third party
engaged to conduct the survey. The screening questions
(1–9) were designed to eliminate ineligible respondents (as
above) and to classify the eligible participants as either RP
or RNP. Eligible participants were asked to state the time
elapsed since they last wrote a prescription for any AED
and whether they had ever prescribed retigabine. To
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identify current RP, eligible participants were further asked
to state whether they currently had patients who were
taking retigabine and the last time they had initiated a
patient on retigabine.
Survey assessment questions (nos. 10–15) were
designed to test understanding of the significant risks
associated with retigabine. Questions were multiple choice
and closed ended. Survey questionnaires were programmed
to ensure that questions were asked in a logical sequence.
Certain questions required a specific answer in order for the
participant to proceed to the next question. Participants
could not go back to a question once the question had been
answered, and could not skip ahead if they did not meet the
criteria to skip questions. Except for data omitted in the
skip pattern, no missing data were expected. All questions
had to be answered in numerical order to complete the
survey; only completed surveys were analyzed. Responses
to questions related to knowledge, attitudes, and behaviors
were categorized as ‘‘correct’’ or ‘‘incorrect’’; ‘‘I don’t
know’’ was categorized as an incorrect response.
2.2 Statistical Methods
The statistical analysis was descriptive; no formal
hypotheses were tested. Counts and percentages were cal-
culated for each item in the questionnaire. Unless otherwise
indicated, percentages were based on the population to
whom a specific question was presented. Confidence
intervals (CIs) were exact two-sided 95 % CIs; no adjust-
ment was performed for multiplicity. Planned subgroup
analyses of the responses to all questions related to
understanding of the risks associated with retigabine were
stratified by respondents’ primary specialties and by the
number of patients with epilepsy treated per month. All
analyses were produced using SAS Software Version 9.1
(Cary, NC, USA).
3 Results
Invitations were sent to 7335 physicians and were followed
up with reminder letters (N = 13,085). The first follow-up
was sent to all non-respondents, whether RP or RNP,
requesting them to complete the survey. When the sample
size for RNP was reached, the survey was closed earlier (28
October 2014) for that group and extended for RP (30
January 2015). In an effort to meet the sample RP target
after the closure of RNP recruitment, a second follow-up
letter was sent to non-respondents asking only current RP
to complete the survey. At the close of recruitment, of 467
respondents who were screened for participation, 426
(91.2 %) were considered eligible. Although RP did not
reach the target of 200, the numbers in each group were
considered sufficient for analysis. Of the 467 physicians
who accessed the survey, 414 (88.7 %) (Table 1) com-
pleted the questionnaire and were included in the analysis
(RP, n = 141; RNP, n = 273).
Demographic information, including country of resi-
dence, type of practice, and number of patients with epi-
lepsy being treated, was collected to further characterize
the participant population included in the analysis
(Table 2). Approximately half (52.7 %) of participants
reported their primary medical specialty as General Neu-
rology; 38.2 % reported a specialty in Neurology with an
Interest in Epilepsy Treatment; 8.5 % self-identified as
Epilepsy specialists/Epileptologists. Approximately half of
the participants were treating 11–50 epilepsy patients
(n = 218, 52.7 %) and about a quarter were treating 1–10
epilepsy patients (n = 100, 24.2 %) per month (data not
shown). The remaining participants treated between 51 and
100 patients (n = 73, 17.6 %) or C101 patients (n = 23,
5.6 %) with epilepsy per month. The highest proportion of
participants came from Spain (44.9 %), followed by Slo-
vakia (15.9 %), the UK (15.2 %), and Belgium (12.3 %)
(Table 2). Almost half (48.9 %) of RP reported having
initiated a patient on retigabine therapy within the previous
6 months; more than a quarter (28.3 %) had done so within
the previous 1–3 months (Table 2).
3.1 Survey Responses
Responses to all questions related to understanding of the
specific risks associated with retigabine are shown in
Table 3. About three-quarters of overall participants
(74.2 %; RP, 77.3 %; RNP, 72.5 %) correctly identified
that the current label indication for retigabine is ‘‘approved
for use in adjunctive treatment of drug-resistant partial
onset seizures where other appropriate drug combinations
Table 1 Survey administration results: recruitment
Invitation process Responses
N (%)a
Invitation letters sent 7335
Reminders sent 13,085
Respondents screened for participationb 467 (100.0)
Respondents eligible to participatec 426 (91.2)
Eligible respondents who completed the survey
(participantsd)
414 (88.7)
a Percentages based on number of screened respondents
b Screened respondents included all physicians who accessed the
online survey using the unique code provided, and answered the first
question with any response
c Respondents were ineligible to participate if they were employees
of GSK or UBC, or government officials
d Participants were those who answered all inclusion/exclusion
questions
Physicians’ Understanding of Retigabine Risks 157
have proved inadequate or have not been tolerated.’’
Overall, 81.9 % (RP, 86.5 %; RNP, 79.5 %) recognized
that the specific risks associated with retigabine included
pigment changes (discoloration) of ocular tissues, includ-
ing the retina. Additionally, 81.6 % overall (RP, 87.2 %;
RNP, 78.8 %) identified that according to the safety
monitoring measures in the current product label, a com-
prehensive ophthalmologic examination is required at
baseline and at least every 6 months thereafter while
treatment is ongoing. Similar percentages among the RP
and RNP groups identified the following specific risks
associated with retigabine: pigment changes (discoloration)
of nails, lips, and/or skin (overall, 71.5 %; RP, 77.3 %;
RNP, 68.5 %); urinary retention (overall, 67.4 %; RP,
75.9 %; RNP, 63.0 %); psychotic disorders including
confusional state and hallucinations (overall, 72.2 %; RP,
78.7 %; RNP, 68.9 %); and QTc prolongation (overall,
65.7 %; RP, 75.2 %; RNP, 60.8 %). Results analyzed by
RP and RNP were similar to the overall analysis, but a
trend indicated a better level of understanding of retiga-
bine-associated risks among RP. Participants overall were
generally familiar with retigabine’s risk profile, particularly
the risk of pigmentary changes (Table 3).
Overall, 99.8 % of participants (RP, 100.0 %; RNP,
99.6 %) correctly acknowledged that action was required if
retinal pigmentation or vision changes were detected in a
patient taking retigabine. Approximately half of participants
(53.1 %; RP, 51.8 %; RNP, 53.8 %) identified that physi-
cians should carefully reassess benefits versus risks before
deciding whether to continue or cease retigabine adminis-
tration. Slightly less than half of participants (48.6 %; RP,
51.1 %; RNP, 47.3 %) selected that retigabine should be
discontinued if another suitable AED was available.
Results summarized by primary specialty for physicians
who completed the survey are shown in Table 4. Analysis
of responses by the primary specialties of Epilepsy/







n % n % n %
Question 3: How would you classify your primary medical specialty?
Epilepsy or epileptology 27 19.1 8 2.9 35 8.5
Neurology with an interest in the treatment of epilepsy 56 39.7 102 37.4 158 38.2
General Neurology 57 40.4 161 59.0 218 52.7
Neuropsychiatry 0 0.0 2 0.7 2 0.5
Neurosurgery 1 0.7 0 0.0 1 0.2
Question 4: In what country is your primary medical practice?
Spain 56 39.7 130 47.6 186 44.9
Slovakia 28 19.9 38 13.9 66 15.9
UK 13 9.2 50 18.3 63 15.2
Belgium 23 16.3 28 10.3 51 12.3
Switzerland 12 8.5 17 6.2 29 7.0
Norway 7 5.0 10 3.7 17 4.1
Hong Kong 2 1.4 0 0.0 2 0.5
Question 9: When was the last time you initiated a patient on
TROBALT (retigabine)?
In the last month 13 9.2 0 0.0 13 3.1
In the last 3 months 27 19.1 5 1.8 32 7.7
Between 3 and 6 months 29 20.6 6 2.2 35 8.5
Between 6 and 12 months 39 27.7 32 11.7 71 17.1
More than 12 months ago 33 23.4 61 22.3 94 22.7
Question not asked (Answered No or I don’t know to Question 7: Have
you ever prescribed TROBALT (retigabine)? (used to ensure that the
sample includes the minimal number of Trobalt prescribers)
a. Yes
b. No [Go to Q10]
169 61.9 169 40.8
Values may not add up to 100 % due to rounding
RNP retigabine non-prescribers, RP retigabine prescribers
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n % (95 % CI) n % (95 % CI) n % (95 % CI)
Question 10: According to the product labelling for TROBALT (retigabine),
TROBALT should now only be used as:
Monotherapy of partial onset seizures 1 0.7 1 0.4 2 0.5
Adjunctive treatment of partial onset seizures 30 21.3 60 22.0 90 21.7
Adjunctive treatment of drug-resistant partial onset seizures
where other appropriate drug combinations have proved
inadequate or have not been tolerateda
109 77.3 198 72.5 307 74.2
(69.5–83.9) (66.8–77.7) (69.7–78.3)
Status epilepticus 0 0.0 0 0.0 0 0.0
I don’t know 1 0.7 14 5.1 15 3.6
Question 11: According to the product labelling for TROBALT
(retigabine), which of the following are potential risks associated
with TROBALT? Answer ‘‘yes,’’ ‘‘no,’’ or ‘‘I don’t know’’
for each of the following:
Pigment changes (discoloration) of ocular tissues,
including the retina
Yesa 122 86.5 217 79.5 339 81.9
(79.8–91.7) (74.2–84.1) (77.8–85.5)
No 7 5.0 20 7.3 27 6.5
I don’t know 12 8.5 36 13.2 48 11.6
Pigment changes (discoloration) of the nails, lips, and/or skin
Yesa 109 77.3 187 68.5 296 71.5
(69.5–83.9) (62.6–74.0) (66.9–75.8)
No 14 9.9 33 12.1 47 11.4
I don’t know 18 12.8 53 19.4 71 17.1
Respiratory distress
Yes 9 6.4 12 4.4 21 5.1
Noa 90 63.8 155 56.8 245 59.2
I don’t know 42 29.8 106 38.8 148 35.7
Urinary retention
Yesa 107 75.9 172 63.0 279 67.4
(68.0–82.7) (57.0–68.7) (62.6–71.9)
No 20 14.2 33 12.1 53 12.8
I don’t know 14 9.9 68 24.9 82 19.8
Ischemic colitis
Yes 6 4.3 2 0.7 8 1.9
Noa 82 58.2 141 51.6 223 53.9
I don’t know 53 37.6 130 47.6 183 44.2
Psychotic disorders (including confusional state and hallucinations)
Yesa 111 78.7 188 68.9 299 72.2
(71.0–85.2) (63.0–74.3) (67.6–76.5)
No 11 7.8 16 5.9 27 6.5
I don’t know 19 13.5 69 25.3 88 21.3
QTc prolongation
Yesa 106 75.2 166 60.8 272 65.7
(67.2–82.1) (54.7–66.6) (60.9–70.3)
No 12 8.5 31 11.4 43 10.4
I don’t know 23 16.3 76 27.8 99 23.9
Rhabdomyolysis
Yes 6 4.3 13 4.8 19 4.6
Noa 69 48.9 110 40.3 179 43.2
I don’t know 66 46.8 150 54.9 216 52.2








n % (95 % CI) n % (95 % CI) n % (95 % CI)
Correctly identified all potential risks of TROBALTb
Yes 60 42.6 90 33.0 150 36.2
(34.3–51.2) (27.4–38.9) (31.6–41.1)
Question 12: According to the current product labelling for TROBALT
(retigabine), patients who are currently on TROBALT require which
of these safety monitoring measures? Answer ‘‘yes’’, ‘‘no’’
or ‘‘I don’t know’’ for each of the following:
Liver function tests
Yes 97 68.8 163 59.7 260 62.8
Noa 32 22.7 52 19.0 84 20.3
I don’t know 12 8.5 58 21.2 70 16.9
A comprehensive ophthalmologic examination
Yesa 123 87.2 (80.6–92.3) 215 78.8 (73.4–83.5) 338 81.6 (77.6–85.3)
No 9 6.4 17 6.2 26 6.3
I don’t know 9 6.4 41 15.0 50 12.1
Blood pressure assessment
Yes 35 24.8 49 17.9 84 20.3
Noa 78 55.3 122 44.7 200 48.3
I don’t know 28 19.9 102 37.4 130 31.4
Measurement of plasma creatinine values
Yes 77 54.6 128 46.9 205 49.5
Noa 42 29.8 52 19.0 94 22.7
I don’t know 22 15.6 93 34.1 115 27.8
Question 13: According to the current product labelling for TROBALT
(retigabine), what should you do if retinal pigmentation or vision
changes are detected in a patient taking TROBALT?
Immediately stop TROBALT
Selected 40 28.4 76 27.8 116 28.0
Not selecteda 101 71.6 197 72.2 298 72.0
Discontinue TROBALT if other suitable treatment
options are available
Selecteda 72 51.1 (42.5–59.6) 129 47.3 (41.2–53.4) 201 48.6 (43.6–53.5)
Not selected 69 48.9 144 52.7 213 51.4
No action required
Selected 0 0.0 1 0.4 1 0.2
Not selecteda 141 100.0 272 99.6 413 99.8
Carefully re-assess the balance of benefits and risks before
deciding whether TROBALT should be continued
Selecteda 73 51.8 (43.2–60.3) 147 53.8 (47.7–59.9) 220 53.1 (48.2–58.0)
Not selected 68 48.2 126 46.2 194 46.9
If TROBALT is continued, the patient should be
monitored more closely
Selecteda 54 38.3 (30.2–46.9) 114 41.8 (35.8–47.9) 168 40.6 (35.8–45.5)
Not selected 87 61.7 159 58.2 246 59.4
CI confidence interval, RNP retigabine non-prescribers, RP retigabine prescribers
a Correct response
b All potential risks of TROBALT are counted as correctly identified if ‘Pigment changes (discoloration) of ocular tissues, including the retina,’ ‘Pigment
changes (discoloration) of the nails, lips, and/or skin,’ ‘Urinary retention,’ ‘Psychotic disorders (including confusional state and hallucinations),’ and ‘QTc
prolongation’ were selected
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Epileptology (n = 35), Neuropsychiatry (n = 2), and Neu-
rosurgery (n = 1) showed higher correct response rates than
the overall analysis results, although the numbers in the latter
two specialties (data not shown) were too small to permit
meaningful conclusions. Responses from specialists in
Neurology with an Interest in the Treatment of Epilepsy
(n = 158), and General Neurology (n = 218) paralleled the
overall analysis results. Results of subgroup analysis by the
number of patients with epilepsy treated per month (1–10;
11–50; 51–100; C 101) (Table 5) showed a higher per-
centage of correct responses for physicians who were treat-
ing higher numbers of patients with epilepsy per month.
Overall, the post hoc subgroup analysis by country
paralleled the main analysis results. Physicians who
completed the survey were from Spain (N = 186, 44.9 %),
Slovakia (N = 66, 15.9 %), the UK (N = 63, 15.2 %),
Belgium (N = 51, 12.3 %), Switzerland (N = 29, 7.0 %),
Norway (N = 17, 4.1 %), and Hong Kong (N = 2, 0.5 %)
(Table 2).
4 Discussion
As part of its European post-marketing commitment and
RMP, GSK distributed an educational letter to neurologists
in the first seven European countries to launch retigabine
(Denmark, Germany, Norway, Slovakia, Spain, Switzer-
land, and the UK), focusing on the risks described in the










n % (95 % CI) n % (95 % CI) n % (95 % CI)
Question 10: According to the product labelling for TROBALT (retigabine),
TROBALT should now only be used as:
Monotherapy of partial onset seizures 1 2.9 1 0.6 0 0.0
Adjunctive treatment of partial onset seizures 4 11.4 38 24.1 48 22.0
Adjunctive treatment of drug-resistant partial onset seizures
where other appropriate drug combinations have proved
inadequate or have not been toleratedb
29 82.9 118 74.7 157 72.0
(66.4–93.4) (67.2–81.3) (65.6–77.9)
Status epilepticus 0 0.0 0 0.0 0 0.0
I don’t know 1 2.9 1 0.6 13 6.0
CI confidence interval
a Results from participants who declared specialties of Neuropsychiatry and Neurosurgery were omitted due to the low numbers of responses
b Correct response
Table 5 Responses to questions related to understanding of the retigabine indication: subgroup analysis by number of patients with epilepsy
treated per month
Question 1 to 10 Patients
n = 100
11 to 50 Patients
n = 218





n % (95% CI) n % (95% CI) n % (95 % CI) n % (95 % CI)
Question 10: According to the product labelling for TROBALT,
TROBALT should now only be used as:
Monotherapy of partial onset seizures 0 0.0 2 0.9 0 0.0 0 0.0
Adjunctive treatment of partial onset seizures 28 28.0 47 21.6 13 17.8 2 8.7
Adjunctive treatment of drug-resistant partial onset
seizures where other appropriate drug combinations
have proved inadequate or have not been tolerateda
66 66.0 163 74.8 57 78.1 21 91.3
(55.8–75.2) (68.5–80.4) (66.9–86.9) (72.0–98.9)
Status epilepticus 0 0.0 0 0.0 0 0.0 0 0.0
I don’t know 6 6.0 6 2.8 3 4.1 0 0.0
CI confidence interval
a Correct response
Physicians’ Understanding of Retigabine Risks 161
approved EU Physician’s Guide for retigabine. Results of a
follow-up online survey (November 2012–October 2013)
to assess the impact of this educational outreach indicated
that physicians generally had adequate knowledge of the
indication for retigabine, but had poorer recall of specific
dose-related information and risk management [12].
The results of the present online survey demonstrate a
satisfactory level of awareness of the most important safety
issues associated with retigabine, including the risk of
retinal pigmentation and potential vision loss. Under-
standing was stronger among RP than RNP, stronger for
physicians who were more specialized in epilepsy man-
agement than for general neurologists, and stronger for
clinicians who provide care for higher rather than lower
numbers of epilepsy patients per month.
Approximately three-quarters of all physicians who
responded to the present survey recognized that the current
licensed indication for retigabine limits this medication to
adjunctive use in patients with partial onset seizures where
other appropriate combinations have proved inadequate or
have been poorly tolerated. More than 80 % of participants
recognized the risk of ocular (including retinal) pigmen-
tation with retigabine and understood that comprehensive
ophthalmologic safety assessments were required. In the
event of detecting either retinal pigmentation or visual
changes, virtually all participants understood that action
was required. However, there was a high level of vari-
ability in the choice of action identified, possibly driven by
a range of different hypothetical patient considerations and
the way the question was presented.
The results of this survey indicate that clinicians have a
satisfactory current level of awareness of changes in the
retigabine product information, and demonstrate that
efforts to communicate recognized risks related to the use
of retigabine have been effective. In establishing a target
sample for the study, it was considered unlikely that reti-
gabine was prescribed by physicians not included on the
mailing list for the DHCP letter in June 2013, as the
approved labelling restricts retigabine to a patient popula-
tion treated only by epilepsy specialists. The results should
be generalizable, therefore, to the population of RP and
clinicians who might use the product.
4.1 Limitations
Although the survey questions were generally straightfor-
ward and readily comprehensible, the responses regarding
action to take in case of retinal pigmentation or vision
changes may have been distorted by the relatively complex
construction of question 13, which differed from that of the
other questions (see Table 3).
This was a voluntary survey and the sample, while
selected, may not be representative of all physicians who
prescribe retigabine. The higher number of responses by
physicians from Spain could possibly be explained by the
exclusive use of e-mail invitations, whereas the invitations
by postal mail in other countries may have been subject to
administrative or institutional filters. In addition, the
mailing list in Spain was larger, providing a larger sample
size than in other countries.
The greater difficulty of recruiting RP than RNP for this
online survey reflects the relatively modest current use of
retigabine internationally. The inclusion of a subpopulation
of RP may have biased the overall results through enrich-
ment, as RP might be assumed to have a better under-
standing of retigabine-associated risks. Finally, physicians
taking the survey were not restricted from access to the
SmPC or other educational materials, which could have
influenced their response. It is possible that a participant
could have researched the answers while taking the test;
however, in an unmonitored, self-administered survey there
is no way to control such behavior, which must be accepted
as a limitation of any such study. In the clinical setting,
however, physicians are free to consult the SmPC.
5 Conclusion
This seven-country survey of physicians who regularly
treat patients with epilepsy followed a DHCP letter as part
of the manufacturer’s RMP. The results indicated a satis-
factory understanding of the most important safety issues
associated with retigabine, an adjunctive therapy for drug-
resistant partial onset seizures, which is indicated only
where other appropriate drug combinations have proved
inadequate or have not been tolerated. Most participants
recognized the appropriate population for retigabine treat-
ment and were aware of the requirement to monitor for
treatment-emergent adverse events including retinal pig-
mentation and vision changes. The level of understanding
appeared higher among physicians who specialized in
epilepsy, physicians treating higher rather than lower
numbers of epilepsy patients per month, and among reti-
gabine prescribers than non-prescribers, although under-
standing was also satisfactory in physicians who did not
manage patients with this antiepileptic therapy.
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